Cargando…
Benefits of dual-release hydrocortisone treatment on central adiposity and health-related quality of life in secondary adrenal insufficiency
PURPOSE: Patients with secondary adrenal insufficiency (SAI) have an increased morbidity and an impaired health-related quality of life (HRQoL), which seems to primarily depend on the sub-optimal replacement of hypoadrenalism with standard glucocorticoid (GC) therapy, and on the inadequate correctio...
Autores principales: | Gasco, V., Giannelli, J., Campioni, L., Arvat, E., Ghigo, E., Grottoli, S., Maccario, M., Giordano, R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9938071/ https://www.ncbi.nlm.nih.gov/pubmed/36251244 http://dx.doi.org/10.1007/s40618-022-01940-1 |
Ejemplares similares
-
Bone safety of dual-release hydrocortisone in patients with autoimmune primary adrenal insufficiency
por: Bioletto, Fabio, et al.
Publicado: (2023) -
Dual-release hydrocortisone vs conventional glucocorticoids in adrenal insufficiency
por: Guarnotta, V, et al.
Publicado: (2019) -
Early Metabolic Benefits of Switching Hydrocortisone to Modified Release Hydrocortisone in Adult Adrenal Insufficiency
por: Bannon, Christopher A. M., et al.
Publicado: (2021) -
Dual-release hydrocortisone improves hepatic steatosis in patients with secondary adrenal insufficiency: a real-life study
por: Guarnotta, Valentina, et al.
Publicado: (2019) -
Development and internal validation of a predictive score for the diagnosis of central adrenal insufficiency when morning cortisol is in the grey zone
por: Bioletto, F., et al.
Publicado: (2022)